Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1995-01-23
1998-10-13
Caputa, Anthony C.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241411, 4241441, 4241531, 435 721, 435 79, 435 793, 435 696, 43525233, 4353201, 435326, 435328, 435332, 435334, 435343, 435348, 435352, 435363, 53038822, 5303873, 536 2353, A61K 39395, G01N 33567, C07K 1600, C07H 2104
Patent
active
058208585
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to methods and compositions for inhibiting CD14 mediated cell activation. More particularly, the present invention relates to molecules that bind the CD14 monocyte antigen at a site which inhibits CD14 mediated cell activation.
2. Description of the Related Art
The correct functioning of a cell depends partly on its ability to communicate with its environment; external stimuli often interact with membrane receptors which, in turn, induce second messengers that ultimately affect transcription factors. The latter then activate or repress the expression of certain genes resulting in a specific pattern of proteins in a given cell.
The transcription factor NF-.kappa.B (nuclear factor-.kappa.B) is induced by a variety of stimuli to contact its DNA-binding motif and regulate a set of genes encoding immunoreceptors, cytokines, and viral proteins. Included among the various factors which can activate NF-.kappa.B is lipopolysaccharide (LPS). LPS, in turn, is intimately involved in the induction of the sepsis syndrome, including septic shock, systemic inflammatory response syndrome, and multiorgan failure.
Sepsis is a morbid condition induced by a toxin, the introduction or accumulation of which is most commonly caused by infection or trauma. The initial symptoms of sepsis typically include chills, profuse sweat, irregularly remittent fever, prostration and the like, followed by persistent fever, hypotension leading to shock, neutropenia, leukopenia, disseminated intravascular coagulation, acute respiratory distress syndrome and multiple organ failure.
Lipopolysaccharide, or endotoxin, is a toxic component found in the outer membrane of all gram-negative microorganisms (e.g., Escherichia coli, Klebsiella pneumonia, Pseudomonas aeruginosa). It has been determined that LPS is a potent and pleiotropic stimulus for immune cells, both in vitro and in vivo (Morrison, D. C. & J. L. Ryan, Annu. Rev. Med., 38:417, 1987; Bone, R. C., Ann. Intern. Med., 115:457, 1991). Compelling evidence supports the toxic role of LPS in that all of the pathophysiological effects noted in humans during gram-negative sepsis can be completely duplicated with purified LPS. The mechanism by which this toxic component activates responsive cells is complex and not fully understood. The host response to gram-negative bacterial infection is dependent upon effector cell recognition of these bacteria and/or LPS and involves serum proteins and cell membrane receptors. While the clearance of bacteria and LPS is via endocytosis and phagocytosis by reticuloendothial cells, concomitant activation of the host immune response by LPS results in secretion of cytokines by activated macrophages which can trigger the exaggerated host responses that occur during gram-negative bacterial infection.
The discovery by Tobias, et al. (J. Exp. Med., 164:777, 1986) of a serum protein, identified as LPS binding protein (LBP), that exhibits high affinity binding to LPS (K.sub.d .apprxeq.10.sup.-9 M.sup.-1), helped to define the fate of LPS once released in vivo. It was demonstrated that this novel protein, with a molecular weight of 60 kD, which is synthesized in the liver is an acute phase serum protein reaching levels of 200 .mu.g/ml in humans. The formation of high affinity LPS/LBP complexes is followed by recognition by macrophages with subsequent release of TNF-.alpha. and other macrophage secretory products (Schumann, R. R., et al., Science, 249:1429, 1990). Additional studies on the effects of LPS complexed with LPB led to the discovery of its specific receptor on the surface of monocytes and macrophages; CD14 (Wright, S. D., et al., Science, 249:1431, 1990). Further analysis with mAbs specific for CD14 revealed that the domain to which one anti-CD14 mAb (3C10; VanVoorhis, W. C., et al., J. Exp. Med., 158:126, 1983) bound was part of, or in close proximity to, the LPS/LBP binding site on CD14. Monoclonal antibody 3C10, by nature of its ability to block LPS/LBP binding to CD14, was capa
REFERENCES:
Tanaka et al Microbiol. Immunol. 29: 959-972 1985.
Goding, "Monoclonal Antibodies: Principles & Practice" Academic Press 1986, pp. 46-47 (Chap 2) and 125-133 (Chap 4).
Steward et al. "Antibody Affinity: Thermodynamic Aspects & Biological Significance" CRC Press, 1983 p. 102.
Casali et al Science 234: 476-479, 1986.
Morrison, Science 229: 1202-1207, 1985.
Better, et al., "Expression of Engineered Antibodies and Antibody Fragments in Microorganisms", Methods in Enzymology, vol. 178, 1989, pp. 476-496.
Putlitz, et al., "Antibody Production inn Baculovirus-Infected Insect Cells", Biotechnology, vol. 8, 1990, pp. 651-654.
Pugin, et al., "Lipopolysaccharide Activation of human Endothelial and Epithelial Cells ins Mediated by Lipopolysaccharide-Binding Protein and Soluble DC14", Proceedings of the National Academy of Sciences USA, vol. 90, Apr. 1993, pp. 2744-2748.
Martin, et al., "Lipopolysaccharide Binding Protein Enhances the Responsiveness of Alveolar Macrophages to Bacterial Lipopolysaccharide. Implications of Cytokine Production in Normal and Injured Lungs", The Journal of Clinical Investigation, vol. 90, Dec. 1992, pp. 2209-2219.
Van Voorhis, et al., "Specific Antimononuclear Phagocyte Nonoclonal Antibodies", Journal of Experimental Medicine, vol. 158, Jul. 1983, pp. 126-145.
Gallay, et al., "Competition Between LPS-Binding Protein (LBP) and Anti-LPS Antibody in LPS-Induced TNF Secretion of Human Monocytes (MO)", Experientia, vol. 48, 1992, p. A66, Abstract No. 384.
Kozbor, et al., "The Production of Monoclonal Antibodies from Human Lymphocytes", Immunology Today, vol. 4, No. 3, 1983, pp. 72-79.
Leturcq Didier J.
Mathison John C.
Moriarty Ann M.
Tobias Peter S.
Ulevitch Richard J.
Caputa Anthony C.
Navarro Mark
The Scripps Research Institute
LandOfFree
Methods and compositions for inhibiting CD14 mediated cell activ does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inhibiting CD14 mediated cell activ, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inhibiting CD14 mediated cell activ will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-310782